Mylan launches generic drug-delivery patch for dementia patients

Mylan (NSDQ:MYL) announced today the U.S. launch of its rivastigmine transdermal drug-delivery patch, a generic version of Novartis‘ (NYSE:NVS) Exelon therapy.
The company’s rivastigmine therapy is indicated for the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan launches generic drug-delivery patch for dementia patients appeared first on MassDevice.

Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Mylan Novartis Source Type: news